Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Tango Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FINANCING PARTICIPANTS INCLUDE FARALLON CAPITAL MANAGEMENT, TCGX, BALYASNY ASSET MANAGEMENT, WOODLINE PARTNERS LP, NEXTECH, INVUS, ADAGE CAPITAL MANAGEMENT LP, BOXER CAPITAL MANAGEMENT, LOGOS CAPITAL, NANTAHALA CAPITAL, ACCOUNTS ADVISED BY T. ROWE PRICE INVESTMENT MANAGEMENT, INC., AND A LARGE INSTITUTIONAL INVESTOR FINANCING PARTICIPANTS INCLUDE FARALLON CAPITAL MANAGEMENT, TCGX, BALYASNY ASSET MANAGEMENT, WOODLINE PARTNERS LP, NEXTECH, INVUS, ADAGE CAPITAL MANAGEMENT LP, BOXER CAPITAL MANAGEMENT, LOGOS CAPITAL, NANTAHALA CAPITAL, ACCOUNTS ADVISED BY T. ROWE PRICE INVESTMENT MANAGEMENT, INC., AND A LARGE INSTITUTIONAL INVESTOR

TANGO THERAPEUTICS ANNOUNCES $225 MILLION FINANCING

BOSTON, OCT. 06, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY ANNOUNCED THAT THE COMPANY WILL HAVE THREE POSTER PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2025, INCLUDING THE FIRST CLINICAL DATA ON THE NOVEL COREST INHIBITOR TNG260 IN NON-SMALL CELL LUNG CANCER. SITC WILL BE HELD NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MARYLAND.

TANGO THERAPEUTICS TO PRESENT FIRST CLINICAL DATA FROM TNG260 AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2025

BOSTON, AUG. 26, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), TODAY ANNOUNCED THAT BARBARA WEBER, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER OF TANGO THERAPEUTICS, IS SCHEDULED TO PARTICIPATE IN A FIRESIDE CHAT AT THE 2025 CANTOR GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, SEPTEMBER 3 AT 2:45-3:15 PM ET.

TANGO THERAPEUTICS TO PARTICIPATE IN THE 2025 CANTOR GLOBAL HEALTHCARE CONFERENCE

 FIRST PATIENT DOSED IN COMBINATION TRIAL OF TNG462 AND REVOLUTION MEDICINES RAS(ON) INHIBITORS   FIRST PATIENT DOSED IN PHASE 1/2 TRIAL WITH TNG456, A BRAIN-PENETRANT MTA-COOPERATIVE PRMT5 INHIBITOR IN DEVELOPMENT FOR GLIOBLASTOMA  BOSTON, AUG. 05, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE30, 2025, AND PROVIDED BUSINESS HIGHLIGHTS. TNG462 HAS THE POTENTIAL TO BE A BEST-IN-CLASS PRMT5 INHIBITOR FOR THE TREATMENT OF MTAP-DEL PANCREATIC AND LUNG CANCERS, AND WE LOOK FORWARD TO SHARING DATA THAT SUPPORT OUR CONVICTION LATER THIS YEAR, SAID BARBARA WEBER, M.D.

TANGO THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS

BOSTON, JUNE 27, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE PHASE 1/2 TRIAL OF TNG462 AND REVOLUTION MEDICINES' DARAXONRASIB (RAS(ON) MULTI-SELECTIVE INHIBITOR) OR ZOLDONRASIB (RAS(ON) G12D-SELECTIVE INHIBITOR) IN PATIENTS WITH MTAP-DELETED AND RAS MUTANT METASTATIC PANCREATIC OR LUNG CANCER.

TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 TRIAL OF TNG462 PLUS REVOLUTION MEDICINES' DARAXONRASIB OR ZOLDONRASIB IN PATIENTS WITH RAS-MUTANT MTAP-DELETED PANCREATIC OR LUNG CANCER

BOSTON, MAY 27, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC.(NASDAQ: TNGX), TODAY ANNOUNCED THAT BARBARA WEBER, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER OF TANGO THERAPEUTICS, IS SCHEDULED TO PARTICIPATE IN A FIRESIDE CHAT AT THE 46TH ANNUAL GOLDMAN SACHS GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, JUNE 10 AT 3:20-3:55 PM ET.

TANGO THERAPEUTICS TO PARTICIPATE IN THE 46TH ANNUALGOLDMAN SACHSGLOBAL HEALTHCARE CONFERENCE

BOSTON, MAY 21, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE TNG456 PHASE 1/2 TRIAL IN PATIENTS WITH MTAP-DELETED SOLID TUMORS, WITH A FOCUS ON GLIOBLASTOMA (GBM). TNG456 IS A NEXT-GENERATION, BRAIN-PENETRANT, MTA-COOPERATIVE PRMT5 INHIBITOR.

TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TNG456 PHASE 1/2 TRIAL IN PATIENTS WITH MTAP-DELETED GLIOBLASTOMAS AND OTHER SOLID TUMORS

 DATA UPDATE FROM ONGOING TNG462 PHASE 1/2 MONOTHERAPY TRIAL EXPECTED 2H 2025  COMBINATION TRIAL OF TNG462 + REVOLUTION MEDICINES RAS(ON) INHIBITORS ON TRACK FOR ENROLLMENT 2Q 2025   CASH POSITION OF $217 MILLION AS OF MARCH 31, 2025; CASH RUNWAY EXTENDED INTO 1Q 2027 WITH REDUCTION OF PRECLINICAL SPEND  BOSTON, MAY 12, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH31, 2025, AND PROVIDED BUSINESS HIGHLIGHTS. ACCUMULATING DATA CONTINUE TO SUPPORT TNG462 AS THE POTENTIAL BEST-IN-CLASS PRMT5 INHIBITOR, SAID BARBARA WEBER, M.D.

TANGO THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSAND PROVIDES BUSINESS HIGHLIGHTS

BOSTON, MAY 01, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), TODAY ANNOUNCED THAT IT WILL REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 12, 2025, BEFORE THE OPEN OF THE U.S. FINANCIAL MARKETS. THE COMPANY DOES NOT INTEND TO HOLD A CONFERENCE CALL.

TANGO THERAPEUTICS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MONDAY, MAY 12, 2025

BOSTON, MARCH 25, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY ANNOUNCED THAT FIVE ABSTRACTS HAVE BEEN ACCEPTED AS POSTER PRESENTATIONS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025, TAKING PLACE APRIL 25-30, 2025, IN CHICAGO, ILLINOIS.

TANGO THERAPEUTICS TO HIGHLIGHT PRECLINICAL DATA ON PRECISION ONCOLOGY PIPELINE WITH FIVE POSTERS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025

Tango Therapeutics, Inc.

TNGX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Tango Therapeutics, Inc.

TNGX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TNGX